Seer (SEER) Net Income (2020 - 2026)
Seer (SEER) posted quarterly Net Income of -$16.8 million for Q1 2026, up 15.6% year-over-year from -$14.6 million in Q1 2025, and down 5.27% quarter-over-quarter from -$16.0 million in Q4 2025.
Seer (SEER) Net Income (2020 - 2026) Analysis & Trends
Seer's Net Income history runs 7 years deep, the most recent figure standing at -$16.8 million for Q1 2026.
- In Q1 2026, Net Income rose 15.6% year-over-year to -$16.8 million; the TTM figure through Mar 2026 stood at -$70.5 million (up 18.15% YoY), while the FY2025 annual figure was -$73.6 million, up 15.25% from the prior year.
- Net Income for Q1 2026 stood at -$16.8 million, down from -$16.0 million in the prior quarter.
- The five-year high for Net Income was -$16.0 million in Q4 2025, with the low at -$66.0 million in Q1 2022.
- The 5-year median for Net Income is -$22.0 million (2024), against an average of -$29.1 million.
- The sharpest annual moves came in 2022 and 2024: Net Income tumbled 260.17% in 2022, then soared 67.48% in 2024.
- Seer's Net Income stood at -$22.5 million in 2022, then increased by 17.86% to -$18.5 million in 2023, then retreated by 18.85% to -$22.0 million in 2024, then advanced by 27.27% to -$16.0 million in 2025, then slipped by 5.27% to -$16.8 million in 2026.
- Business Quant data shows SEER's Net Income at -$16.8 million in Q1 2026, -$16.0 million in Q4 2025, and -$18.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 930.12 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Seer | 230.63 Mn | 230.63 Mn | 1.51 Mn | -16.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -16.90 Mn |
| Mar 31, 2026 | -16.84 Mn |
| Dec 31, 2025 | -15.99 Mn |
| Sep 30, 2025 | -18.23 Mn |
| Jun 30, 2025 | -19.42 Mn |
| Mar 31, 2025 | -19.95 Mn |
| Dec 31, 2024 | -21.99 Mn |
| Sep 30, 2024 | -21.33 Mn |
| Jun 30, 2024 | -22.85 Mn |
| Mar 31, 2024 | -20.68 Mn |
| Dec 31, 2023 | -18.50 Mn |
| Sep 30, 2023 | -58.98 Mn |
| Jun 30, 2023 | -27.34 Mn |
| Mar 31, 2023 | -63.60 Mn |
| Dec 31, 2022 | -22.53 Mn |
| Sep 30, 2022 | -34.68 Mn |
| Jun 30, 2022 | -26.60 Mn |
| Mar 31, 2022 | -65.96 Mn |
| Dec 31, 2021 | -19.72 Mn |
| Sep 30, 2021 | -47.32 Mn |